Abstract:Donor lymphocyte infusions (DLI) are a well-established and widely employed strategy to increase the graft-versus-tumor (GvT) effect of allogeneic hematopoietic stem cell transplantation (HSCT) and/or to sustain donor engraftment in case of mixed chimerism [1, 2]. Unfortunately, the use of DLI is associated with an important non-relapse mortality (NRM) mainly secondary to the induction of graft-versus-host disease (GvHD) [3]. To optimize the risk/benefit ratio of such adoptive immunotherapy, Simona Pagliuca and colleagues recently reported on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Bone Marrow Transplantation (EBMT) society, a series of consensus-based recommendations for the administration of unmanipulated DLI after allogeneic HSCT [4]. In the published recommendations, the EBMT CTIWP proposes the use of T cell doses adapted to the DLI indication (prophylactic, pre-emptive and therapeutic), the donor type (matched related donor, MRD; matched unrelated donor, MUD; and mismatched unrelated donor, MMUD, or haploidentical donor) and the time of infusion (3 months or 6 months or later after allogeneic HSCT) [4]. For prophylactic DLI, EBMT experts recommend a first DLI dose administered between 3- and 6-months post transplantation of 1 × 10e5 CD3/kg independently of donor type. If administered later than 6 months after transplantation, a first dose of 1 × 10e6/kg was recommended for DLI from matched related donors (MRD) as well as matched unrelated donors (MUD) while the dose was reduced to 5 × 10e5/kg for originating from mismatched unrelated donors/haploidentical donors (MMUD/haplo). For pre-emptive DLI administered between 3- and 6-months post transplantation, EBMT's experts recommended a first DLI dose of 1–5 × 10e5/kg if in case of MRD and of 1 × 10e5 CD3/kg in case of MUD or MMUD/haplo. If the pre-emptive DLI is given later than 6 months after transplantation, the first recommended DLI dose is 1–3 × 10e6 CD3/kg if MRD, 1 × 10e6 /kg if MUD and 5 × 10e5/kg if MMUD/haplo. Finally, in case of relapse, therapeutic DLI at a starting dose of 1 × 10e7 CD3/kg for MRD or MUD, and of 1 × 10e6/kg for MMUD/Haplo was recommended. Given the absence of robust prospective data, the EBMT 2024 recommendations were mostly based on expert consensus and their external validation is therefore needed to support their widespread use in clinical practice. To evaluate the utility of these recommendations on real-world data, we retrospectively analyzed a cohort of 162 patients receiving DLI after allogeneic HSCT at our center between January 2010 and December 2023. Patients' characteristics are summarized in Table 1. Median age at allogeneic HSCT was 51 years (range 15–74). Transplantation indication was acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in 57% of patients, acute lymphoblastic leukemia (ALL) in 12%, lymphoma or chronic lymphocytic leukemia (CLL) in 13%, chronic myeloid leukemia (CML) in 7%, and other hematological malignancies in 6%. First dose of DLI was infused at a median time of 214 days (range 60–3753 days) after allogeneic HSCT. No patient received immunosuppressive drugs at time of DLI. Thirty-eight percent of patients had a history of GvHD (acute GvHD, n = 61 and/or chronic GvHD, n = 11) resolved at time of DLI. Median number of DLI was 2 (range 1–7). Table 1 Patients' characteristics. Full size table

The Cell Composition of Infused Donor Lymphocyte Has Different Impact in Different Types of Allogeneic Hematopoietic Stem Cell Transplantation.

Donor Lymphocyte Infusion after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies.

Superiority of Preemptive Donor Lymphocyte Infusion Based on Minimal Residual Disease in Acute Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation

A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment

Modified Donor Lymphocyte Infusion‐associated Acute Graft‐versus‐host Disease after Haploidenticalt‐cell‐replete Hematopoietic Stem Cell Transplantation: Incidence and Risk Factors

Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation

Prophylactic Modified Donor Lymphocyte Infusion after Allogeneic Peripheral Blood Stem Cell Transplantation for Very High-Risk Hematological Malignancies: Low Incidence of Relapse Without Increasing the Risk of Graft-Versus-Host Disease

Risk Stratification-Directed Donor Lymphocyte Infusion Could Reduce Relapse Of Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering

Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation

Donor Lymphocyte Infusion for the Treatment of Leukemia Relapse after HLA-mismatched/haploidentical T-cell-replete Hematopoietic Stem Cell Transplantation.

Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms

Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells

Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?

A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.

Prophylactic Modified Donor Lymphocyte Infusion after Low-Dose ATG-F-based Haploidentical HSCT with Myeloablative Conditioning in High-Risk Acute Leukemia: a Matched-Pair Analysis

Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation]

Donor Lymphocyte Infusion (DLI) Post Allogeneic Stem Cell Transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A Longitudinal Retrospective Study Using Peripheral Blood (PB) CD34 + and CD3 + Donor Chimerism (DC) Monitoring